US sign-up averts major EU crisis, but India, China actives still problematic
This article was originally published in Scrip
New EU rules on importing Active Pharmaceutical Ingredients coming into force on 2 July may bring problems for European manufacturers and patients, industry sources are still warning. But the situation for companies could be better than feared because the major sources of APIs such as the US, India and China, have made it clear that they will, after all, comply with the EU regulation.
You may also be interested in...
Softening provisions to make EU-wide joint clinical assessments voluntary would make proposed legislation on HTA cooperation redundant, says Eurordis.
Plans for EU-wide Joint Clinical assessments will come under scrutiny at an EU council meeting next week.
Pfizer’s Ibrance has won conditional reimbursement in England while more data is gathered to reduce some uncertainty.